Lyrica Cr Tablet, Film Coated, Extended Release
NDC Package 58151-246-93

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Lyrica Cr (pregabalin) tablets is a medication used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection. This formulation utilizes a tablet, film coated, extended release delivery system. Marketed by Viatris Specialty Llc, this product is identified by NDC 58151-246 and is authorized under FDA application NDA209501.

Identification & Billing

NDC Package Code
58151-246-93
Package Description
30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
58151024693
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Lyrica Cr
Non-Proprietary Name
Pregabalin
Substance Name
Pregabalin
Dosage Form
Tablet, Film Coated, Extended Release - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer; the tablet is formulated in such manner as to make the contained medicament available over an extended period of time following ingestion.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
This medication is used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection.
DEA Schedule
Schedule V (CV) Substances

Regulatory & Marketing

Labeler Name
Viatris Specialty Llc
Product Type
Human Prescription Drug
FDA Application #
NDA209501
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
11-26-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 58151-246-93 identifies a specific commercial package of 30 tablet, film coated, extended release in 1 bottle of Lyrica Cr, a human prescription drug labeled by Viatris Specialty Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This tablet, film coated, extended release is formulated for oral use and contains pregabalin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Viatris Specialty Llc on November 26, 2024. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection.

How is this Viatris Specialty Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 58151024693. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
58151-246-93
11-Digit CMS (5-4-2)
58151-0246-93

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.